Notably, treatment with demethylating agents such as 5-Aza-CdR has been shown to restore GSTM5 expression and inhibit tumor cell proliferation and migration, reinforcing the potential therapeutic value of targeting DNA methylation in cancer. The gene discussed is GSTM5; the disease is cancer.